Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 7Phase EARLY_PHASE1 4Phase NA 2Phase 1/2 2Phase 3 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1Neuroblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × 3-Iodobenzylguanidine × Clear all
NCT04614766 2024-04-29

SPORE-3

University of Iowa

Phase 1/2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT00798148 2012-06-04

131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma

Tehran University of Medical Sciences

Phase 1/2 Unknown
10 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡